Tag Archives: Liana Moussatos

Wedbush Sticks to Its Hold Rating for Regulus (RGLS)

In a report released yesterday, Liana Moussatos from Wedbush reiterated a Hold rating on Regulus (RGLS – Research Report), with a price target of $1.00. The company’s shares closed last Monday at $0.88. According to TipRanks.com, Moussatos is a 2-star

Wedbush Remains a Buy on Intercept Pharma (ICPT)

In a report issued on February 7, Liana Moussatos from Wedbush maintained a Buy rating on Intercept Pharma (ICPT – Research Report), with a price target of $257.00. The company’s shares closed last Monday at $95.17. According to TipRanks.com, Moussatos

United Therapeutics (UTHR) Received its Third Buy in a Row

After Credit Suisse and Oppenheimer gave United Therapeutics (NASDAQ: UTHR) a Buy rating last month, the company received another Buy, this time from Wedbush. Analyst Liana Moussatos reiterated a Buy rating on United Therapeutics today and set a price target

Wedbush Keeps a Buy Rating on Aquestive Therapeutics (AQST)

Wedbush analyst Liana Moussatos maintained a Buy rating on Aquestive Therapeutics (AQST – Research Report) on January 31 and set a price target of $35.00. The company’s shares closed last Monday at $4.05, close to its 52-week low of $2.95.

Miragen Therapeutics (MGEN) Receives a Buy from Wedbush

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Miragen Therapeutics (MGEN – Research Report), with a price target of $10.00. The company’s shares closed last Monday at $2.06. According to TipRanks.com, Moussatos is a

Wedbush Sticks to Their Buy Rating for Allena Pharmaceuticals (ALNA)

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Allena Pharmaceuticals (ALNA – Research Report), with a price target of $26.00. The company’s shares closed last Monday at $2.18, close to its 52-week low of